Abiopharma

🔍 Assis Alessandra Faccin (Executive)

Company: ASHLAND INC. (ASH)

Report Date: 2026-07-27

Detailed Transactions and Holdings:

• Acquired 3,215 shares of Common Stock at $66.38 per share (Direct)
  Date: 2026-07-27 | Code: M | equity_swap_involved: false | shares_owned_after: 9,099.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 884 shares of Common Stock at $66.38 per share (Direct)
  Date: 2026-07-27 | Code: F | equity_swap_involved: false | shares_owned_after: 8,215.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 3,215 shares of Restricted Stock Unit (Derivative)
  Date: 2026-07-27 | Code: M | equity_swap_involved: false | shares_owned_after: 9,646.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F1

Footnotes:

• F1: Balance includes additional common stock or restricted stock units acquired in lieu of cash dividends.
• F2: Payment of tax liability by withholding securities incident to the vesting of Restricted Stock Units acquired pursuant to Ashland's incentive plan as approved by the shareholders and exempt pursuant to Rule 16b-3.
• F3: Each Restricted Stock Unit represents a right to receive one (1) share of Ashland Common Stock.
• F4: On July 25, 2024, the Reporting Person was granted 15,234 restricted stock units, vesting over a three-year period, with 20% vesting on July 25, 2025, 20% vesting on July 25, 2026, and 60% vesting on July 25, 2027, provided that the Reporting Person remains in continuous employment with the Issuer.